Evolution of Self-reported Neuropsychiatric Symptoms After Switching from Dolutegravir/Abacavir/Lamivudine to Bictegravir/Emtricitabine/Tenofovir Alafenamide: Results from the Randomized DOBINeuro Trial

Abstract Introduction Central nervous system adverse events (AE) have been a cause of discontinuation of dolutegravir-containing therapy, especially in combination with abacavir. The main aim of the study was to evaluate whether the switch to bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/...

Full description

Bibliographic Details

Published in:	Infectious Diseases and Therapy
Main Authors:	Barbara Rossetti, Micol Ferrara, Lucia Taramasso, Francesca Bai, Francesca Lombardi, Nicoletta Ciccarelli, Miriam Durante, Francesca Alladio, Federica Bonazza, Ilaria Rancan, Francesca Montagnani, Antonio Di Biagio, Antonella d’Arminio Monforte, Maurizio Zazzi, Massimiliano Fabbiani, for DOBINeuro study group
Format:	Article
Language:	English
Published:	Adis, Springer Healthcare 2024-11-01
Subjects:	HIV Bictegravir Neuropsychiatric symptoms Switch
Online Access:	https://doi.org/10.1007/s40121-024-01083-1